The demo can show the product. Before the demo, the buyer is already estimating whether the transition will be workable, governable and worth the organisational effort.
The implementation question begins before implementation
Healthcare AI vendors often reserve implementation details for sales or onboarding. Some information must remain contextual or confidential. But when the public journey says almost nothing about transition, the buyer is asked to enter a meeting without knowing what kind of organisational commitment is being considered.
The buyer may already be asking: Which systems are involved? Who must participate? What changes in the workflow? How is local testing performed? What happens when the system is unavailable? Which responsibilities remain with our organisation? These are not late-stage technical details. They shape whether the opportunity deserves a next step.
The hidden implementation price
The effective price of a complex health technology includes more than the licence. It can include integration work, internal project time, clinical review, training, governance, monitoring, exception handling, procurement effort and the political cost carried by the internal champion.
A company does not need to publish a universal timeline or fixed workload estimate when those depend on the buyer. It can still make the structure visible. A useful implementation overview distinguishes vendor responsibilities, buyer responsibilities, assumptions, dependencies and the conditions that require local validation.
Five questions public information should begin answering
1. What changes in the current workflow? 2. What systems, data and technical dependencies are involved? 3. Who owns implementation, validation, training and ongoing monitoring? 4. What does a pilot need to prove, and what would stop it? 5. What remains organisation-specific?
These questions help the buyer understand the shape of the transition without pretending that a generic website can complete local diligence.
Implementation evidence should be staged
Visible publicly: the general workflow, implementation phases, prerequisites, typical responsibilities and the route to further review.
Shared after a serious enquiry: technical architecture, integration guidance, resource assumptions, support model and detailed implementation plan.
Confidential under NDA: proprietary technical information, sensitive security details or partner-specific documentation.
Testing for the proposed use case: local acceptance criteria, workflow measures, safety checks, data validation and pilot outcomes.
What companies can do
Create a public implementation orientation page that describes the transition in plain language. Add a responsibility map showing what the vendor provides and what the buyer must validate. Define a pilot as a decision process, not a product trial: name the question, baseline, measures, success criteria, stop conditions and required output.
Finally, connect implementation evidence to the stakeholders who will use it. Clinical leadership needs workflow and safety. IT needs integration and data requirements. Operations needs ownership and exception handling. Finance needs total cost and measurable outcomes. The internal champion needs a route that connects them.
The Archoric perspective
The destination is not enough. The transition has to feel survivable. Archoric examines whether the public evidence gives stakeholders enough orientation to justify deeper review, then designs the evidence routes required for controlled and buyer-specific diligence.
Sources
- UK Government, A buyer's guide to AI in health and care
- FDA, Transparency for Machine Learning-Enabled Medical Devices: Guiding Principles
- NIST, AI Risk Management Framework
- WHO, Ethics and governance of artificial intelligence for health
- FAIR-AI, A practical framework for appropriate implementation and review of AI in healthcare
- Early pipeline framework for assessing vendor AI solutions to support return on investment
- DECIDE-AI reporting guideline
- ONC HTI-1 Final Rule
- HHS Healthcare and Public Health Cybersecurity Performance Goals
- FDA, Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions
- LinkedIn and Bain, The Principles of Buyability
- Forrester, 2026 State of Business Buying
What does your public evidence currently enable stakeholders to understand?
The Proof-to-Decision™ Assessment applies a governed review to the company’s actual evidence, stakeholder questions and public routes.
Explore the Assessment